



Neuro-Ophthalmology Update (04/09/22 @ 8 a.m. ET)

Saturday, April 9, 2022

Wills Eye Auditorium

Conference Description:

[Click Here to Sign Up for the Livestream](#)

Wills Eye Hospital is re-opening Saturday Updates to a limited number of guests to attend in-person.

If you would like to attend in-person, please select the in-person option [when registering for the event](#).

We look forward to expanding our capacity to welcome even more guests in the coming months!

With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.

At the conclusion of the course, participants should be able to:

- 1 Discuss important new advances in the etiologies, diagnosis, and treatment/prevention of eye diseases.
- 2 Identify basic and clinical vision research that can be transformed into improved clinical care.
- 3 Assess the role of new technologies in the evaluation and treatment of eye diseases.
- 4 Describe factors that impact the effective delivery of the highest quality eye care for the public.
- 5 Identify clinical, scientific, and ethical issues confronting the profession.
- 6 Obtain information and tools through multiple facets to help ophthalmologists deliver high and efficient quality of care.

Accreditation Statement:

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Wills Eye Hospital designates this live educational activity for a maximum of 4.00 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Statement:

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

Name of individual	Individual's role in activity	Name of Ineligible Company(s) / Nature of Relationship(s)
Usma Chatha, MD	Faculty	Nothing to disclose - 04/03/2022
Kalla A. Gervasio, MD	Faculty	Nothing to disclose - 03/04/2022
April Lao, MD	Faculty	Nothing to disclose - 02/02/2022
Mark L Moster, MD	Faculty	Speakers Bureau-Sanofi Grant or research support-GenSight Biologics Consulting Fee-GenSight Biologics - 11/19/2021
Sarah Thornton , MD	Faculty	Nothing to disclose - 03/16/2022
Robert C Sergott, MD	Faculty, Planner	Membership on Advisory Committees or Review Panels, Board Membership, etc.-Roche Membership on Advisory Committees or Review Panels, Board Membership, etc.-Horizon Therapeutics Membership on Advisory Committees or Review Panels, Board Membership, etc.-Heidelberg Engineering Membership on Advisory Committees or Review Panels, Board Membership, etc.-Bristol Myers Squibb Membership on Advisory Committees or Review Panels, Board Membership, etc.-Clene Nanomedicine Membership on Advisory Committees or Review Panels, Board Membership, etc.-GenSight Biologics Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis Membership on Advisory Committees or Review Panels, Board Membership, etc.-Merck - 03/16/2022
Ralph C. Eagle Jr., MD	Other Planning Committee Member	Stocks or stock options, excluding diversified mutual funds-Merck - 01/15/2022

